Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04674722
Overview
To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2-single domain antibody (Product Code Name: 99mTc-NM-02 and 188Re-NM-02) SPECT/CT imaging of HER2 expression and radionuclide therapy in Breast Cancer. The SPECT/CT results will compare with the existing gold standard " HER2 expression detection" by biopsy tissue immunohistochemistry (IHC) and/or Fluorescence in Situ Hybridization (FISH) method, and 18F-FDG PET/CT imaging. It also to establish a new theranostic method for non-invasive HER2 expression detection and radionuclide therapy in breast cancer using 99mTc/188Re labeled anti-HER2 single domain antibody.
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Early Phase 1
Contacts
Jinhua Zhao, PhD (Principal Investigator)
zhaojinhua1963@126.com
0086-21-37798352
Lingzhou Zhao, PhD
zlz-330@163.com
0086-21-37798354
ClinicalTrials.gov
NCT04674722Help us improve your experience